Japanese firm Mitsui & Co. has participated as a lead investor in a Series B round financing of Koios Medical, a US-based healthcare technology and digital medicine company.

This investment was facilitated by Mitsui's wholly-owned subsidiary, MBK Healthcare Management (MHM), which is Mitsui's dedicated healthcare operating platform. MHM is also the largest shareholder of IHH Healthcare Berhad, a leading premium healthcare provider operating 80 hospitals in 10 countries with more than 15,000 licensed beds.  

With regulatory clearances from the US Food and Drug Administration and CE Marks, Koios develops artificial intelligence (AI)-powered clinical decision support software for radiologists, endocrinologists, and other trained physicians and technicians, which are vendor agnostic solutions that can be integrated into most picture archiving and communication systems (PACS) workstations for breast and thyroid ultrasound analysis and reporting.

Koios’s software aims to empower physicians in their decision-making process, and enhance the patient experience, identify cancers in earlier stages, reduce unnecessary procedures and minimize the stress associated with false positive findings. 

"AI-enabled decision support solutions such as Koios's are increasingly important to alleviate the rising pressures in radiology and healthcare systems worldwide brought on by ageing populations, escalating healthcare costs and a healthcare workforce shortage. MHM aims to facilitate collaborations between Mitsui's existing portfolio companies and Koios, as well as help Koios expand its presence globally to enable better patient care," commented Takeshi Saito, Managing Director & Chief Executive Officer of MHM.